Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > repost-here some details u may have missed from presentation
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(74)
•••
Comment by GunnerGon Feb 14, 2020 10:24am
74 Views
Post# 30691112

RE:repost-here some details u may have missed from presentation

RE:repost-here some details u may have missed from presentationRealstups, please post the link to your misinformation.

Its easy to do.  We would all love to see the document you are quoting.

Here is the link for the latest corporate peresentation and page 11 bears no resemblance to what you are posting.

 Click Here for February 2020 Presentation

The highlight on that page is Ryplazim anticipated FDA approval has been pushed out to 2021. 

Original BLA for Ryplazim filed April 5, 2017.  
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities